Purpose
29] 3
Outcome measures included time to first severe asthma exacerbation (primary outcome) and number of severe asthma exacerbations
Authors' conclusions
The duration of formoterol is longer than that of albuterol, which is usually used as a rapid reliever
This systematic review and meta-analysis evaluates whether, for patients with poorly controlled asthma, switching to single inhaler combination budesonide-formoterol maintenance and reliever therapy is associated with longer time to first severe asthma exacerbation compared with a step up or continuation of Global Initiative for Asthma
1% in salmeterol + fluticasone + SABA group was noted
Background
Overview of the safety of regular formoterol or salmeterol in adults with asthma
Clinical evidence has shown that asthma management using budesonide/formoterol (Symbicort®) maintenance and reliever therapy (SMART) provides a simpler and more effective treatment strategy than traditional approaches with short-acting β 2-agonist (SABA) therapy
06 vs 1
For patients 12 years or older with moderate to severe persistent asthma, a single ICS/formoterol inhaler (i
Singh D
The aim of this study was to perform a systematic review and meta-analysis on the data published from
As a result, there was an absolute increase of an additional 21 children (95% CI 4 to 45) suffering such an SAE of any cause for every 1000 children treated over six months with either regular formoterol or salmeterol monotherapy, whilst for combination therapy the increased risk was an additional three children (95% CI 1 fewer to 12 more)
garding the risk of mortality on combination formoterol vs
In stud-ies comparing formoterol and budesonide to salmeterol and flutica - sone, there were 77 in the formoterol arm and 68 in the salmeterol Ratings & Reviews
Fluticasone / salmeterol has an average rating of 4
However, formoterol had a more rapid onset of action than salmeterol, equal to that of salbutamol
CD004106
The present study was designed to compare the fixed combination of beclomethasone and formoterol in a hydrofluoroalkane Modulite® (Chiesi Farmaceutici, Parma, Italy) pressurised metered-dose inhaler (pMDI), with a combination of budesonide and formoterol administered via a Turbuhaler® (AstraZeneca, Lund, Sweden) dry powder inhaler (DPI)
Budesonide/formoterol maintenance and reliever therapy prolonged time to first severe exacerbation versus budesonide/formoterol and salmeterol/fluticasone propionate fixed maintenance dose